Eli Lilly (LLY)

Latest stories mapped to LLY

Everything Newsig has mapped to LLY, newest first — no importance filter. Topic pages list critical and high-importance stories only.

• 2026-10-16 Lilly, Pfizer, J&J among winners of EU drug recommendations this month
• 2026-10-16 Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up
• 2026-10-16 Lilly wins EU backing for Foundayo weight-loss pill
• 2026-10-15 US delays small imports rule that raised alarm over prescription drug costs
• 2026-10-15 Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets
• 2026-10-15 Micron Technology is lagging Eli Lilly, Berkshire Hathaway, and maybe soon Walmart in market cap
• 2026-10-15 Eli Lilly's Omvoh boosted by new ulcerative colitis, Crohn's data
• 2026-10-15 GLP-1s are linked to lower psychiatric hospitalizations: study
• 2026-10-14 Citizens reiterates Prelude Therapeutics stock rating on Lilly deal
• 2026-10-13 Walmart to cover some GLP-1s, inhalers and insulin for employees at no cost as it expands benefits
• 2026-10-13 Walmart to cover GLP-1s, insulin at no cost for workers in benefits push - report
• 2026-10-13 Walmart to offer employees 250-plus medications at no cost in expanded health benefits
• 2026-10-13 AbbVie, Eli Lilly among mega-cap healthcare stocks with A+ profitability grades
• 2026-10-12 BMO cuts Novo Nordisk stock price target on Ozempic headwinds
• 2026-10-09 Combining Eli Lilly's Taltz with Zepbound could enhance psoriasis, metabolic benefits
• 2026-10-09 Eli Lilly-backed TRexBio prices $117M US IPO at $14 per share
• 2026-10-07 Dutch court orders Merck to halt Keytruda sales in Europe
• 2026-10-07 Pharma lobby group sues Trump administration over MFN pricing
• 2026-10-07 GLP-1s sidelined in WHO’s first-ever guidelines targeting child obesity
• 2026-10-07 PepsiCo running out of time to meet Elliott-inspired targets as GLP-1 threat intensifies